Table 1.

Characteristics of observational studies included in this systematic review

Study, YearCountryType of StudySample SizeMean Age (years)Stage of CKDBaseline 25(OH)D/ PTH LevelInterventionStudy Duration (months)Outcomes Reported
Published studies
    Al Aly, 2007 (28)United StatesProspective cohort66703 and 416.6/23150,000 IU of ergocalciferol once a week for 12 weeks, then once a month for an additional 3 months.625(OH)D, PTH, calcium, phosphorus
    Bagnis, 1998 (29)ItalyProspective cohort15615 (PD)7/157Calcidiol (25 hydroxyvitamin D3) 100 μg/d (= 4000 IU/d)125(OH)D, 1,25(OH)2D calcium, phosphorus
    Blair, 2008 (30)United StatesRetrospective318625 (HD)18.35/45350,000 IU of ergocalciferol once weekly6PTH, calcium, phosphorus
    Bouchard, 2008 (31)CanadaProspective cohort27NR5 (PD)12.5/5964440 IU ergocalciferol once weekly125(OH)D, 1,25(OH)2D, PTH
    Courbebaisse, 2009 (19)FranceProspective cohort9446Transplant14/76Four oral doses of 100,000 IU of cholecalciferol once every 2 weeks from 4 to 6 months after renal transplantation (intensive phase), then every 2 months until 12 months (maintenance phase).1225(OH)D, PTH, calcium, phosphorus
    Deville, 2006 (32)United StatesProspective cohort85673 to 518/17850,000 IU of ergocalciferol twice weekly for 8 weeks followed by 800 IU/day. Patients with 25(OH)D levels between 16 and 30 ng/ml (40 and 75 nmol/L) were prescribed 50,000 IU/month for 2 months, followed by 800 IU/day. Patients with 25(OH)D levels >30 ng/ml (75 nmol/L) were prescribed 800 IU/day.1225(OH)D, PTH, calcium
    Jean, 2009 (33)FranceProspective cohort107665 (HD)13.3/307.9Cholecalciferol (100,000 IU) monthly1525(OH)D, 1,25(OH)2D, PTH, calcium, phosphorus
    Saab, 2007 (34)United StatesRetrospective118595 (HD)16.9/304.2Ergocalciferol (50,000 IU) monthly by the nursing staff during the HD.625(OH)D, PTH, calcium, phosphorus
    Shah, 2005 (35)United StatesProspective cohort23475 (PD)6.9/302.150,000 IU once weekly125(OH)D, 1,25(OH)2D, PTH, calcium, phosphorus
    Tokmak, 2008 (36)GermanyProspective cohort64NR5 (HD)6.9/21320,000 IU cholecalciferol once weekly925(OH)D, PTH, calcium, phosphorus
    Zisman, 2007 (37)United StatesProspective cohort52723 to 519.5/159.550,000 IU weekly for 4 weeks depending on severity of deficiency followed by 1200 IU/d1225(OH)D, 1,25(OH)2D, PTH, calcium, phosphorus
Unpublished studies
    Balon, 2009 (38)SloveniaProspective cohort97NRHD11.4/280.740,000 IU of cholecalciferol monthly325(OH)D, PTH, calcium, phosphorus
    Finn, 2007 (39)United StatesRetrospective20NRCKD 315.7/18450,000 IU once weekly325(OH)D, 1,25(OH)2D, PTH, calcium, phosphorus
    Matias, 2009 (40)PortugalProspective cohort15862.8HD22.3/267Oral cholecalciferol per KDOQI guidelines1225(OH)D, 1,25(OH)2D, PTH, calcium, phosphorus
    Pesenson, 2007 (41)United StatesProspective cohort14NRTransplant17.7/137.250,000 IU daily125(OH)D, 1,25(OH)2D, PTH, calcium, phosphorus
    Shannon, 2007 (42)United StatesProspective cohort38NRNondialysis-dependent CKD34.43/NR50,000 IU weekly for 4 to 12 weeks, then monthlyNR25(OH)D, Epo
    Lopes, 2009 (20)BrazilProspective cohort33NRNondialysis-dependent CKD11.3/11650,000 IU weekly until 25(OH)D level >30 ng/ml and then monthly625(OH)D, 1,25(OH)2D, PTH, calcium, phosphorus
  • Vitamin D levels are shown in ng/ml and PTH levels are shown in pg/ml. HD, hemodialysis; PD, peritoneal dialysis; Epo, Epogen usage per week; NR, not reported.